CorriXR Therapeutics

CorriXR Therapeutics is a transformative biotechnology company with breakthrough in vivo gene editing therapeutic technology. The company’s initial focus is on oncology, particularly on difficult-to-treat solid tumors starting with squamous cell carcinoma of the lung. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new clinically relevant cancer therapies in areas of unmet medical need, starting with squamous cell carcinoma of the lung.